PSD3 downregulation confers protection against fatty liver disease

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Rosellina M. Mancina - , University of Gothenburg (Autor:in)
  • Kavitha Sasidharan - , University of Gothenburg (Autor:in)
  • Anna Lindblom - , AstraZeneca (Autor:in)
  • Ying Wei - , Ionis Pharmaceuticals (Autor:in)
  • Ester Ciociola - , University of Gothenburg (Autor:in)
  • Oveis Jamialahmadi - , University of Gothenburg (Autor:in)
  • Piero Pingitore - , University of Gothenburg (Autor:in)
  • Anne Christine Andréasson - , AstraZeneca (Autor:in)
  • Giovanni Pellegrini - , AstraZeneca (Autor:in)
  • Guido Baselli - , Università degli Studi di Milano (Autor:in)
  • Ville Männistö - , University of Eastern Finland (Autor:in)
  • Jussi Pihlajamäki - , University of Eastern Finland (Autor:in)
  • Vesa Kärjä - , University of Eastern Finland (Autor:in)
  • Stefania Grimaudo - , Università degli Studi di Palermo (Autor:in)
  • Ilaria Marini - , Università degli Studi di Milano (Autor:in)
  • Marco Maggioni - , IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano (Autor:in)
  • Barbara Becattini - , University of Gothenburg (Autor:in)
  • Federica Tavaglione - , University of Gothenburg (Autor:in)
  • Carly Dix - , AstraZeneca (Autor:in)
  • Marie Castaldo - , AstraZeneca (Autor:in)
  • Stephanie Klein - , Ionis Pharmaceuticals (Autor:in)
  • Mark Perelis - , Ionis Pharmaceuticals (Autor:in)
  • Francois Pattou - , Université de Lille, Centre Hospitalier Universitaire (CHU) de Lille (Autor:in)
  • Dorothée Thuillier - , Université de Lille (Autor:in)
  • Violeta Raverdy - , Université de Lille, Centre Hospitalier Universitaire (CHU) de Lille (Autor:in)
  • Paola Dongiovanni - , IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano (Autor:in)
  • Anna Ludovica Fracanzani - , IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano, Università degli Studi di Milano (Autor:in)
  • Felix Stickel - , Universität Zürich (Autor:in)
  • Jochen Hampe - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Stephan Buch - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Panu K. Luukkonen - , University of Helsinki, Minerva Foundation Institute for Medical Research Helsinki, Yale University (Autor:in)
  • Daniele Prati - , Università degli Studi di Milano (Autor:in)
  • Hannele Yki-Järvinen - , University of Helsinki, Minerva Foundation Institute for Medical Research Helsinki (Autor:in)
  • Salvatore Petta - , Università degli Studi di Palermo (Autor:in)
  • Chao Xing - , University of Texas Southwestern Medical Center (Autor:in)
  • Clemens Schafmayer - , Universität Rostock (Autor:in)
  • Elmar Aigner - , Paracelsus Medizinischen Privatuniversität (Autor:in)
  • Christian Datz - , Paracelsus Medizinischen Privatuniversität (Autor:in)
  • Richard G. Lee - , Ionis Pharmaceuticals (Autor:in)
  • Luca Valenti - , Università degli Studi di Milano (Autor:in)
  • Daniel Lindén - , AstraZeneca, University of Gothenburg (Autor:in)
  • Stefano Romeo - , University of Gothenburg, Sahlgrenska University Hospital, Magna Græcia University (Autor:in)

Abstract

Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a missing heritability component. Using a candidate gene approach, we identify a locus (rs71519934) at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein (L186T) that reduces susceptibility to the entire spectrum of FLD in individuals at risk. PSD3 downregulation by short interfering RNA reduces intracellular lipid content in primary human hepatocytes cultured in two and three dimensions, and in human and rodent hepatoma cells. Consistent with this, Psd3 downregulation by antisense oligonucleotides in vivo protects against FLD in mice fed a non-alcoholic steatohepatitis-inducing diet. Thus, translating these results to humans, PSD3 downregulation might be a future therapeutic option for treating FLD.

Details

OriginalspracheEnglisch
Seiten (von - bis)60-75
Seitenumfang16
FachzeitschriftNature metabolism
Jahrgang4
Ausgabenummer1
PublikationsstatusVeröffentlicht - Jan. 2022
Peer-Review-StatusJa

Externe IDs

Scopus 85123974742
PubMed 35102341

Schlagworte

Ziele für nachhaltige Entwicklung